Clinical trials: Familial Primary Pulmonary Hypertension
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt
Hypertension, Pulmonary
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II.
- Trial name
- NCT00004754
- Testing
- epoprostenol
- Sponsor
- National Center for Research Resources (NCRR)
Infant, Newborn, Infant, Low Birth Weight
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- Preemie iNO (NCT00016523)
- Testing
- Inhaled nitric oxide
- Where
- 17 sites in United States
- Volunteers
- 420 people
- Sponsor
- NICHD Neonatal Research Network
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial…
- Trial name
- FUTURE 2 (NCT00319020)
- Testing
- Bosentan
- Volunteers
- 33 people
- Sponsor
- Actelion
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Artery Hypertension
Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH
The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the repeatability of laboratory and…
- Trial name
- REPEAT-PAH (NCT05421949)
- Testing
- Exercise group
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Diabetes Mellitus, Hypertension
Evidence-based Laboratory Test Order Sets in Primary Care
Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.
- Conditions
- Diabetes Mellitus, Hypertension, Cardiovascular Diseases, Fatigue
- Trial name
- NCT02950142
- Testing
- CPOE with order sets for lab testing, CPOE without order sets for lab testing
- Where
- Belgium
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Idiopathic Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
Due to vasodilatory properties of the NO, one of the therapeutic approaches for IPAH is oral use of nitric oxide precursors (10).
- Trial name
- NCT01683981
- Testing
- L-Citrulline Malate
- Where
- Iran
- Volunteers
- 25 people
- Sponsor
- Masih Daneshvari Hospital
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Arterial Hypertension
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
The current aims to combine analysis of different inflammatory biomarkers and BMPR2 mutations, which are currently analyzed in each patient diagnosed with idiopathic or familial PAH, to establish an earlier diagnosis and…
- Trial name
- NCT02959723
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Arterial Hypertension, Ayerza Syndrome
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
- Conditions
- Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
- Trial name
- NCT00086463
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Actelion
Pulmonary Artery Hypertension
Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH).
- Trial name
- NCT06429579
- Testing
- Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy, Only conventional drug therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertension;Pulmonary;Primary
Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension
This study plans to learn more about activity levels in children with pulmonary hypertension. Pulmonary hypertension is a condition where the pressure in the lungs is higher than normal. This can affect the person's heart.
- Trial name
- NCT04745000
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
OBJECTIVES: I. Describe the psychosocial response of parents and caretakers who learn cardiopulmonary resuscitation (CPR) techniques for infants at high risk for respiratory or cardiac arrest. II.
- Conditions
- Pulmonary Hypertension, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Trial name
- NCT00004805
- Testing
- CPR instruction
- Volunteers
- 500 people
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Arterial Hypertension, Iron Deficiency
IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension.
- Trial name
- NCT01447628
- Testing
- Saline, Ferinject or CosmoFer
- Where
- 5 sites in China, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- Imperial College London
Pulmonary Hypertension
Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension
Primary pulmonary hypertension (PPH) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.
- Trial name
- NCT00173537
- Testing
- for BMPR II study, BMPRII
- Where
- Taiwan
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension
The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that…
- Trial name
- FUTURE-1 (NCT00319267)
- Testing
- Bosentan
- Volunteers
- 36 people
- Sponsor
- Actelion
Pulmonary Hypertension
Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients
Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD…
- Trial name
- NCT01913457
- Testing
- Ultrasound Doppler
- Where
- 2 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Echosense Ltd.
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center